Bioasis Technologies (FRA:107) Pre-Tax Income : €-2.12 Mil (TTM As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Bioasis Technologies's pretax income for the three months ended in Nov. 2022 was €-0.72 Mil. Its pretax income for the trailing twelve months (TTM) ended in Nov. 2022 was €-2.12 Mil. Bioasis Technologies's pretax margin was -659.63%.

Bioasis Technologies Pre-Tax Income Historical Data

The historical data trend for Bioasis Technologies's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Pre-Tax Income Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Pre-Tax Income

Get a 7-Day Free Trial

-3.42

-2.32

-2.80

0.46

-2.05

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Pre-Tax Income	Get a 7-Day Free Trial															-0.89	-0.39	-0.17	-0.83	-0.72

Competitive Comparison of Bioasis Technologies's Pre-Tax Income

For the Biotechnology subindustry, Bioasis Technologies's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioasis Technologies's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Pre-Tax Income falls into.

Bioasis Technologies Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Bioasis Technologies's Pretax Income for the fiscal year that ended in Feb. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-2.493	+	0.895	+	-0.453	+	0	+	-0.0010000000000003
	=	-2.05

Bioasis Technologies's Pretax Income for the quarter that ended in Nov. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-0.51	+	-0.055	+	-0.155	+	0	+	0.0010000000000001
	=	-0.72

Pre-Tax Income for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.12 Mil.

Bioasis Technologies (FRA:107) Pre-Tax Income Explanation

Bioasis Technologies's Pretax Margin for the quarter that ended in Nov. 2022 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-0.719	/	0.109
	=	-659.63%

Bioasis Technologies Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies (FRA:107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines